Pfizer published results from its phase III oral clinical trials for tofacitinib in ulcerative colitis in the New England Journal of Medicine. Researchers concluded, “In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.”
Lumendi released its new endoscopic accessory DiLumen EIP at Digestive Disease Week, May 6 through May 9 in Chicago. Lumendi is in the process of conducting a post-market outcome study. The FDA awarded the DiLumen FDA 510(k) clearance in December 2016.
The FDA awarded 510(k) clearance to endoscopic diagnostics company Crospon’s Endoflip System with Flip Topography Module. The new system allows physicians to assess patient motility disorders during endoscopy.
Olympus is extending the EndoTherapy Solutions portfolio it’s displaying at Digestive Disease Week, May 6 through May 9 in Chicago.
The FDA awarded Interscope’s EndoRotor System marketing clearance. Physicians can use the EndoRotor System in colorectal surgery.
gMed’s, a Modernizing Medicine company, gGastro EHR can now report Consumer Assessment of Healthcare Providers and Systems Outpatient and Ambulatory Surgery Survey data to some vendors.
More articles on gastroenterology:
Autonomously capsule robot could improve colonoscopy acceptance, accuracy
Tofacitinib effective as induction, maintenance therapy in ulcerative colitis treatment — 6 key notes
Unique enzyme could allow gluten-sensitive patients to digest gluten — 3 key notes
